Encube Ethicals announces new high potency topical manufacturing suite

21 Apr 2019

Company's $4 million investment reflects market need for contract service providers who can provide innovative and cost-effective topical manufacturing capabilities for products that include highly potent actives.

Encube Ethicals, an integrated pharmaceutical organisation specialising in topical, transdermal and complex delivery solutions, has announced that its new high potency manufacturing facility for topical formulations is now fully operational.

Encube Ethicals announces new high potency topical manufacturing suite

The new 350-m2 facility, at its site in Goa, follows a $4 million investment by the company last year to bolster its topical manufacturing capabilities. It has an in-house isolator technology that caters for topical products, which include highly potent active pharmaceutical ingredients (HPAPIs), such as pesticides, immunosuppressants and skin oncology drugs.

The facility, which was built in response to customer and market demand for Encube’s services, adds an additional manufacturing line to the company’s portfolio, taking the total number of SKUs manufactured at the site to over 400.

Mehul Shah, managing director at Encube Ethicals, who founded the business in 1998, said: “There is a real gap in the market for contract service providers that can provide innovative and cost-effective topical manufacturing capabilities for products that include highly potent actives.

“As a result, we have experienced high demand for these services and chose to invest in a new facility to increase our capacity. Now that we’re fully operational, we can continue to cater for new small pharma, biotech and virtual customers, as well as continue to support our current multi-national customers who are entering the high potency topical space.”

Based in Mumbai and Goa, the company has over 20 years’ experience of providing an end-to-end, high-quality service for topical products.

The team at the new facility are experienced in handling a number of immunosuppressant topicals including, Tacrolimus and Primecrolimus, as well as skin oncology products such as Fluorouracil. High potency manufacturing is carried out using sophisticated material handling equipment to ensure safety of the operators and the product.

Read More

Related news

Can the industry really claim it's 'business as usual'?

Can the industry really claim it's 'business as usual'?

19 May 2020

ChargePoint Technology's Chief Commercial Officer says "yes" it can.

Read more 
HKBU scientists develop technique to eliminate drug side effects

HKBU scientists develop technique to eliminate drug side effects

19 May 2020

The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

Read more 
Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

19 May 2020

The certification is expected to instill greater 'supply' trust with clients, particularly during the current pandemic.

Read more 
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

18 May 2020

CDMO is contracted to produce multiple clinical batches from German facility

Read more 
Pharmapack expert recommends holistic approach to sustainability

Pharmapack expert recommends holistic approach to sustainability

18 May 2020

Although the industry might be 30% along its sustainability journey, greater interoperability is needed from materials to devices.

Read more 
KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

12 May 2020

Company's manufacturing methods and processes reviewed by an independent third-party auditor to ensure the products have the highest-quality ingredients possible.

Read more 
Characterizing virus and virus-like particles

Characterizing virus and virus-like particles

12 May 2020

New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.

Read more 
Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

12 May 2020

CDMO says it has made "notable changes" to its supply chain processes to ensure continuing supply of medicines during COVID-19 pandemic

Read more 
AI technology company launches with Novartis and Sarepta deals

AI technology company launches with Novartis and Sarepta deals

11 May 2020

Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.

Read more 
Demand for immunity products to be sustained long-term says SIRIO

Demand for immunity products to be sustained long-term says SIRIO

11 May 2020

Movement towards healthy lifestyles and preventative supplements the lasting behavioural change post COVID-19.

Read more